News - Biotechnology

Filter

Current filters:

Biotechnology

Popular Filters

226 to 250 of 2104 results

Nanomedicines market to reach $177.6 billion globally in 2019

08-01-2014

The global market for nanomedicine was valued at $78.54 billion in 2012 and is expected to reach a value…

BiotechnologyCardio-vascularGlobalMarkets & MarketingOncology

Promedior appoints William Hodder as vice president of business development

08-01-2014

US biotech company Promedior has announced that industry veteran William Hodder has joined the company…

BiotechnologyBoardroomPromediorUSA

Epizyme shares soar as Celgene deal triggers $25 million milestone payment

Epizyme shares soar as Celgene deal triggers $25 million milestone payment

08-01-2014

US biotech company Epizyme has announced the achievement of the proof of concept milestone in the EPZ-5676…

BiotechnologyCelgeneEpizymeFinancialOncologyResearchUSA

Neurocrine rockets on positive Phase II data for tardive dyskinesia treatment

08-01-2014

Shares of Neurocrine Biosciences were up almost 80% yesterday after it announced that NBI-98854, a small…

BiotechnologyNeurocrine BiosciencesNeurologicalResearchUSA

AstraZeneca in deal with Immunocore to develop novel cancer therapies

AstraZeneca in deal with Immunocore to develop novel cancer therapies

08-01-2014

UK privately-held biotech firm Immunocore has signed an oncology research collaboration and licensing…

AstraZenecaBiotechnologyImmunocoreLicensingMedImmuneOncologyResearch

Capricor Therapeutics and Janssen collaborate on cell therapy program

Capricor Therapeutics and Janssen collaborate on cell therapy program

07-01-2014

California, USA-based Capricor Therapeutics says it has executed a collaboration agreement and exclusive…

BiotechnologyCAP-1002Capricor TherapeuticsCardio-vascularJanssen BiotechJohnson & JohnsonLicensing

Australian biotech shares soar in 2013

Australian biotech shares soar in 2013

07-01-2014

The Australian stock exchange achieved an average gain of 53.6% across the biotech sector in 2013, according…

AlchemiaAustraliaBionomicsBiotechnologyFinancial

NicOx highlights progress in bid to focus on ophthalmology

07-01-2014

French biotech firm NicOx SA (NYSE Euronext Paris: COX) says it has made significant progress in 2013…

BiotechnologyFinancialFranceNicOxOphthalmics

DiaVacs' type 1 diabetes drug candidate gains orphan designation from FDA

DiaVacs' type 1 diabetes drug candidate gains orphan designation from FDA

06-01-2014

US clinical-stage biotech firm DiaVacs has granted orphan drug designation for its type 1 diabetes mellitus…

BiotechnologyDiabetesDiaVacsDV-0100North AmericaRegulationUSA

Marina Biotech and Mirna Therapeutics amend deal for microRNA-based therapeutics

06-01-2014

USA-based RNAi-based drug discover Marina Biotech and privately-held biotech firm Mirna Therapeutics…

BiotechnologyLicensingMarina BiotechMirna TherapeuticsMRX34Oncology

Orphan designation for NPS Pharma’s Natpara in Europe

04-01-2014

The European Commission has granted orphan drug designation to US biotech firm NPS Pharmaceuticals Natpara…

BiotechnologyNatparaNPS PharmaceuticalsRare diseasesRegulation

FDA lifts partial clinical hold on Cell Therapeutics’ tosedostat

FDA lifts partial clinical hold on Cell Therapeutics’ tosedostat

02-01-2014

US biotech firm Cell Therapeutics has received notification from the US Food and Drug Administration…

BiotechnologyCell TherapeuticsNorth AmericaOncologyRegulationtosedostatUSA

Amgen and UCB’s romosozumab shows significant increase in BMD

Amgen and UCB’s romosozumab shows significant increase in BMD

02-01-2014

US biotech firm Amgen and partner UCB of Belgium have announced positive results from a Phase II trial…

AmgenAnti-Arthritics/RheumaticsBiotechnologyForteoFosamaxResearchromosozumabUCB

Agilis Biotherapeutics and Intrexon collaborate on rare genetic disease

01-01-2014

US synthetic biology companies Agilis Biotherapeutics and Intrexon have entered an exclusive channel…

Agilis BiotherapeuticsBiotechnologyBoardroomFinancialIntrexonManagementRare diseasesResearch

Walvax Biotech to take 64% stake in Genor BioPharma for around $49 million

Walvax Biotech to take 64% stake in Genor BioPharma for around $49 million

31-12-2013

China’s Walvax Biotech has revealed it plans to acquire a controlling 64% equity stake in Shanghai’s…

Asia-PacificBiosimilarsBiotechnologyChinaMergers & AcquisitionsOncology

Senesco enters merger accord with Fabrus

31-12-2013

USA-based biotech firm Senesco Technologies has agreed to terms and executed a non-binding Letter of…

BiotechnologyFabrusMergers & AcquisitionsOncologySenesco Technologies

UK’s NICE says yes to Cell Thera’s non-Hodgkin’s lymphoma drug Pixuvri

UK’s NICE says yes to Cell Thera’s non-Hodgkin’s lymphoma drug Pixuvri

31-12-2013

US biotech firm Cell Therapeutics’ Pixuvri (pixantrone), a treatment for an aggressive type of cancer…

BiotechnologyCell TherapeuticsEuropeOncologyPixuvriPricingRegulation

Emerging markets and patent cliffs create supply chain management issues for pharma, white paper warns

Emerging markets and patent cliffs create supply chain management issues for pharma, white paper warns

26-12-2013

A new white paper commissioned by logistics company DHL warns that global life sciences and health care…

BiotechnologyGlobalMarkets & MarketingPharmaceuticalProduction

Surprise US FDA approval for United Thera’s Orenitram ER for PAH

Surprise US FDA approval for United Thera’s Orenitram ER for PAH

23-12-2013

In what was seen by some observers as unexpected, the US Food and Drug Administration has approved United…

BiotechnologyNorth AmericaOrenitramRegulationRespiratory and PulmonaryTreprostinilUnited Therapeutics

Biologics reimbursement trends in Argentina, Brazil and Mexico

Biologics reimbursement trends in Argentina, Brazil and Mexico

23-12-2013

Novel biologics must demonstrate improvements in efficacy, safety and cost-benefit compared with currently…

Anti-Arthritics/RheumaticsArgentinaBiotechnologyBrazilMalaysiaMarkets & MarketingOncologyPricingSouth America

Actelion’s PAH drug Opsumit approved in EU

Actelion’s PAH drug Opsumit approved in EU

22-12-2013

Switzerland-based Actelion has received European Commission approval for Opsumit (macitentan), a novel…

ActelionBiotechnologyEuropeOpsumitRegulationRespiratory and Pulmonary

Sobi terminates deal with Rare Disease Therapeutics for Orfadin distribution

Sobi terminates deal with Rare Disease Therapeutics for Orfadin distribution

20-12-2013

Nordic biotech firm Swedish Orphan Biovitrum (STO: SOBI) has terminated its distributor agreement with…

BiotechnologyLegalLicensingNorthern EuropeOrfadinRare Disease TherapeuticsSobi

Kemal Malik appointed Bayer board member with responsibility for innovation

Kemal Malik appointed Bayer board member with responsibility for innovation

20-12-2013

The supervisory board of German drugs and chemicals major Bayer (BAYN: DE) has appointed Kemal Malik…

BayerBiotechnologyBoardroomGermanyPharmaceuticalUK

Novogen establishes global collaboration to target brain cancer treatment

Novogen establishes global collaboration to target brain cancer treatment

20-12-2013

Australian biotech company Novogen (ASX: NRT) has signed a sponsored research agreement with Cornell…

AustraliaBiotechnologyNovogenOncologyResearchUSA

226 to 250 of 2104 results

Back to top